About these slide decks and video commentaries
This series of freely downloadable, state-of-the-art slide decks has been developed to complement and build on the content of the current Back to Basics section of the Lp(a) Forum. Back to Basics is designed to introduce Forum members to the growing recognition of Lp(a) as an important, independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, even when LDL-cholesterol levels are low.
These Back to Basic slide decks take viewers from early concepts about the science of Lp(a), through evidence-based knowledge about its role in ASCVD and aortic valve stenosis, to practical implications for Lp(a) testing and patient care in daily practice.
Alongside each slide deck, a member of the Lp(a) Forum’s Editorial Board of internationally recognised experts from the scientific and clinical communities presents a video commentary. This reflects their own specialist insights into the specific aspects of Lp(a) research included in the slide deck, together with their current and potential future application in primary and secondary care.
Lilly has provided arms’ length sponsorship funding for the Lp(a) Forum Back to Basics Educational Resources but has had no influence or control over the content.
Latest slide deck and video commentary now available
Cardiovascular risk assessment in primary care: What does Lp(a) add?
This slide deck looks at cardiovascular risk scores commonly used in primary care, and reviews the impact of adding Lp(a) test results to their predictive capacity, based on biobank, clinical trial and real world data. It also includes recent data linking Lp(a) testing to greater initiation of lipid lowering therapy and reduction in cardiovascular events.
Commentary by: Professor Henry Ginsberg, Columbia University Medical Center, New York, USA
Previous slide decks and video commentaries
Slide Deck 1 – What is Lp(a)?
This slide deck is a guide to the structure, function, production and clearance of Lp(a), its genetics, atherogenicity, interaction with the arterial wall, impact on plaque progression, and proatherogenic, proinflammatory and prothrombotic activities.
Commentary by: Professor John Chapman, Pitié-Salpêtrière University Hospital, INSERM, Paris France
Slide Deck 2 – Elevated Lp(a): Who is at risk?
This slide deck discusses non-modifiable risk factors for elevated Lp(a) (eg. ethnicity, genetics, menopause) and modifiable risk factors (eg: kidney disease, thyroid disease), and guideline recommendations for managing patients in these high risk groups.
Commentary by: Dr Jaimini Cegla, Imperial College London, UK
Slide Deck 3 – Lp(a) Testing
This slide deck considers the practicalities of establishing Lp(a) testing in routine clinical practice, interpreting test results, and counselling patients, and demonstrates the cost savings that can be made from Lp(a) testing in identifying and addressing a patient’s cardiovascular risk.
Commentary by: Professor Karol Watson, University of California, Los Angeles, USA
Slide Deck 4 – Lp(a) and cardiovascular disease
This slide deck reviews the epidemiologic and genetic data supporting the association between elevated Lp(a) and atherosclerotic cardiovascular disease, including myocardial infarction, aortic valve stenosis, peripheral artery disease, abdominal aortic aneurysm, heart failure and ischaemic stroke.
Commentary by: Professor Pia Kamstrup, Copenhagen University Hospital, Denmark
